Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients
Main Authors: | Cameron Mura, Saskia Preissner, Susanne Nahles, Max Heiland, Philip E. Bourne, Robert Preissner |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-07-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-021-00689-y |
Similar Items
-
A Birds-Eye (Re)View of Acid-Suppression Drugs, COVID-19, and the Highly Variable Literature
by: Cameron Mura, et al.
Published: (2021-08-01) -
Prediction of oral squamous cell carcinoma based on machine learning of breath samples: a prospective controlled study
by: Sophia Mentel, et al.
Published: (2021-10-01) -
Gender- and age-related differences in the width of attached gingiva and clinical crown length in anterior teeth
by: Marie-Elise Jennes, et al.
Published: (2021-06-01) -
“5.560”
by: Héctor Castiñeira López -
Contributions to the study of histamine antagonists in man
by: Bain, William Alexander
Published: (1953)